Bernard Bihain

Biography

Bernard created Genclis in 2004. After a doctorate in medicine from the Université Libre de Bruxelles, Bernard started a surgical internship that he left to focus exclusively on research as part of a postdoctoral fellowship. Columbia University, New York, USA. He is then appointed Assistant Professor of Physiology at the University of Louisiana, New Orleans, USA. Bernard received the Inserm Research Director's Competition and became Professor and President of the Department of Biochemistry at the University of Rennes, where the Inserm 391 unit was created, which he directs. He then took over the management of Genset's functional genomics department, a publicly traded genomic company sold to Merck-Serono. He then becomes CSO of Valigen that he leaves to devote himself to the creation of Genclis. He has actively contributed to the emergence of genomic technologies, his surgeon pragmatism is the engine of Genclis translational activities. Bernard is the author of more than 50 publications in peer-reviewed journals. His works are cited in more than 5000 scientific articles.

Research Interest

Bioinformatics and system biology